ModifiedBlue Cross Blue Shield of VermontPolicy 2.01.VT47

Light Therapy for Dermatologic Conditions

Customize your policy alerts

Sign up for bcbsvermont Policy 2.01.VT47 alerts

Get alerted when Policy 2.01.VT47 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Medical necessity and coverage criteria for PUVA, UVB phototherapy, targeted phototherapy, and home ultraviolet light systems for dermatologic conditions.

Policy Summary

PayerBlue Cross Blue Shield of Vermont

PolicyLight Therapy for Dermatologic Conditions

Policy CodePolicy 2.01.VT47

Change TypeModified

Effective DateAug 1, 2026

Last ReviewMar 1, 2026

Next Review DateMar 1, 2027

Key ActionVerify the member’s benefits and applicable prior approval requirements before providing treatment.

SourceLink

POLICY UPDATE CHANGES

Home ultraviolet light system criteria now require outpatient phototherapy to have been utilized, demonstrated benefit, and be expected to continue long-term.

4Light therapy modalities addressed

9Potentially medically necessary UVB indications

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedBlue Cross Blue Shield of VermontPolicy 2.01.VT47

Light Therapy for Dermatologic Conditions

Customize your policy alerts

Sign up for bcbsvermont Policy 2.01.VT47 alerts

Get alerted when Policy 2.01.VT47 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Medical necessity and coverage criteria for PUVA, UVB phototherapy, targeted phototherapy, and home ultraviolet light systems for dermatologic conditions.

Policy Summary

PayerBlue Cross Blue Shield of Vermont

PolicyLight Therapy for Dermatologic Conditions

Policy CodePolicy 2.01.VT47

Change TypeModified

Effective DateAug 1, 2026

Last ReviewMar 1, 2026

Next Review DateMar 1, 2027

Key ActionVerify the member’s benefits and applicable prior approval requirements before providing treatment.

SourceLink

POLICY UPDATE CHANGES

Home ultraviolet light system criteria now require outpatient phototherapy to have been utilized, demonstrated benefit, and be expected to continue long-term.

4Light therapy modalities addressed

9Potentially medically necessary UVB indications

3Investigational targeted phototherapy indications

3x weeklyInitial home-treatment frequency

8CPT codes requiring prior approval

Medical Necessity and Coverage Criteria

PUVA medically necessary indications

PUVA may be considered medically necessary when the applicable condition and treatment-response criteria are met.

Qualifying PUVA indication

Severe, disabling psoriasis that is unresponsive to conservative therapy.
Examples include topical corticosteroids, coal/tar preparations, and ultraviolet light.
Severe refractory atopic dermatitis that is unresponsive to conservative therapy.
Examples include topical corticosteroids, coal/tar preparations, and ultraviolet light.
Severe refractory pruritus that is unresponsive to conservative therapy.
Examples include topical corticosteroids, coal/tar preparations, and ultraviolet light.
Cutaneous T-cell lymphoma, including mycosis fungoides or Sézary syndrome.
Vitiligo that is unresponsive to conservative therapy.
Examples include topical corticosteroids, coal/tar preparations, and ultraviolet light.

UVB medically necessary indications

UVB treatment may be considered medically necessary for any of the following conditions.

Qualifying UVB indication

Mild-to-moderate psoriasis that is unresponsive to conservative treatment.
Moderate-to-severe psoriasis.
Severe refractory atopic dermatitis that is unresponsive to conservative therapy.
Severe refractory pruritus that is unresponsive to conservative therapy.
Cutaneous T-cell lymphoma, including mycosis fungoides or Sézary syndrome.
Vitiligo criterion

Targeted phototherapy medically necessary indications

Targeted phototherapy may be considered medically necessary for any of the following conditions.

Qualifying targeted phototherapy indication

Mild-to-moderate psoriasis that is unresponsive to conservative treatment.
Moderate-to-severe localized psoriasis comprising less than 20% of body surface area for which PUVA or narrowband UVB are indicated.<20% body surface area
Cutaneous T-cell lymphoma, including mycosis fungoides or Sézary syndrome.
Morphea (localized scleroderma) that is unresponsive to conservative treatment.

Home ultraviolet light systems

Home ultraviolet light systems may be considered medically necessary when ALL of the following are met.

Home ultraviolet light system requirements

Qualifying condition
- Extensive psoriasis involving more than 5% of body surface area.>5% body surface area
  Extensive involvement of the palms or soles is sufficient for coverage.
- Severe atopic dermatitis.
- Severe pruritus.
- Cutaneous T-cell lymphoma.
- Vitiligo criterion

Investigational targeted phototherapy

Targeted phototherapy is considered investigational for the following indications.

Investigational targeted phototherapy indication

First-line treatment of mild psoriasis.
Generalized psoriasis or psoriatic arthritis.
Treatment of vitiligo.

Light therapy alone for actinic keratosis is not medically necessary. Photodynamic therapy for actinic keratosis is addressed separately under the Blue Cross VT Dermatologic Applications of Photodynamic Therapy policy.

Home-based psoralens with ultraviolet A (PUVA) are not medically necessary.

Light therapy is not medically necessary for indications not listed in this policy.

Codes, Thresholds, and Billing Categories

Home-use ultraviolet light systemsHCPCSCovered

E0691-E0694

Ultraviolet Light Systems for Home Use

Ultraviolet light laser treatmentCPT

96920-96922

Ultraviolet light laser treatment for inflammatory disease (psoriasis), according to the surface area of skin treated

Other ultraviolet and photochemotherapy servicesCPT

96900	Dermatologic use of ultraviolet light, also known as phototherapy
96910-96913	Photochemotherapy

CPT CodesCPT

96900	Actinotherapy (ultraviolet light).
96910	Photochemotherapy; tar and ultraviolet B (Goeckerman treatment) or petrolatum and ultraviolet B.
96912	ultraviolet B Photochemotherapy; psoralens, and ultraviolet A (PUVA).
96913	Photochemotherapy (Goeckerman and/or PUVA) for severe photoresponsive dermatoses requiring at least 4-8 hours of care under direct supervision of the physician (includes application of medication and.
96920	Laser treatment for inflammatory skin disease (psoriasis); total area less.
96921	Laser treatment for inflammatory skin disease (psoriasis); total area 250-500 sq.
96922	Laser treatment for inflammatory skin disease (psoriasis); total area over 500 sq cm.
96999	Unlisted special dermatological service or procedure.

HCPCS CodesHCPCS

E0691	Ultraviolet light therapy system, includes bulbs/lamps, timer and eye protection; treatment area 2 square feet or less.
E0692	Ultraviolet light therapy system panel, includes bulbs/lamps, timer and eye.
E0693	Ultraviolet light therapy system panel, includes bulbs/lamps, timer and eye protection, 6-foot panel.
E0694	therapy system in 6-foot cabinet, includes bulbs/lamps, timer and eye.
J8999	Prescription drug, oral, chemotherapeutic, not otherwise specified Unlisted code will suspend for medical review.

Extensive psoriasis for home-system coverage

Body-surface-area thresholdMore than 5% of the body surface area affected

Palm or sole involvementExtensive involvement of the palms or soles is sufficient for coverage

Applies toUltraviolet light systems for home use

Initial home-treatment frequency

Initial treatment requirementThe member initially requires ultraviolet light treatments

Minimum frequency

Prior Approval, Documentation, and Coverage Risks

Prior Authorization

Verify Benefits and Service Requirements

Verify the member’s benefits before providing light therapy. Confirm whether the service requires prior approval and whether the member’s contract includes any applicable limitation or exclusion.

Prior Authorization

Prior Approval Required for Listed CPT Services

Obtain prior approval before billing the specified phototherapy and laser-treatment services.

CPT 96900 — Actinotherapy (ultraviolet light)
CPT 96910, 96912, 96913 — Photochemotherapy and PUVA services
CPT 96920-96922 — Laser treatment for inflammatory skin disease

Policy Scope and Therapy Overview

This policy addresses photochemotherapy with psoralen plus ultraviolet A (PUVA), broadband or narrowband ultraviolet B (UVB), targeted phototherapy, and home ultraviolet light systems for dermatologic conditions. Covered indications are primarily refractory or severe conditions, including psoriasis, atopic dermatitis, pruritus, cutaneous T-cell lymphoma, vitiligo, morphea, pityriasis lichenoides chronica, and lichen planus.

Clinical and Coding Definitions

Psoriasis severity

Mild psoriasisLess than 5% of body surface area

Moderate psoriasis5% to 10% of body surface area

Severe psoriasisMore than 10% of body surface area

Additional assessmentLesion characteristics and impact on quality of life are also taken into account

Localized involvementLesions on the hands, feet, or genitalia that cause disability may be classified as moderate-to-severe

Targeted phototherapy

Treatment approach

Policy Summary

PayerBlue Cross Blue Shield of Vermont

PolicyLight Therapy for Dermatologic Conditions

Policy CodePolicy 2.01.VT47

Change TypeModified

Effective DateAug 1, 2026

Last ReviewMar 1, 2026

Next Review DateMar 1, 2027

Key ActionVerify the member’s benefits and applicable prior approval requirements before providing treatment.

SourceLink

On This Page

Vitiligo that is unresponsive to conservative therapy.

Vitiligo involving more than 10% of body surface area.>10% body surface area

Morphea (localized scleroderma) that is unresponsive to conservative treatment.

Pityriasis lichenoides chronica criterion

Pityriasis lichenoides chronica that is unresponsive to conservative therapy.
Widespread pityriasis lichenoides chronica involving more than 10% of body surface area.>10% body surface area

Lichen planus that is unresponsive to conservative therapy.

Vitiligo that is unresponsive to conservative therapy.
Vitiligo involving more than 10% of body surface area.>10% body surface area

Morphea (localized scleroderma).

Pityriasis lichenoides chronica.

Additional requirements

The condition is refractory because adequate trials of topical regimens have failed; the disease is unmanageable or resistant to treatment.
The member initially requires ultraviolet light treatments at least 3 times a week.At least 3 treatments per week initially
Outpatient phototherapy has been utilized, has demonstrated benefit, and is expected to be long-term.
Light therapy treatment is prescribed by a dermatologist.

At least 3 times a week

Applies toUltraviolet light systems for home use

Localized psoriasis for targeted phototherapy

Body-surface-area thresholdLess than 20% of body surface area

ConditionModerate-to-severe localized psoriasis

Applicable treatmentPUVA or narrowband UVB must be indicated

Vitiligo or pityriasis lichenoides chronica UVB threshold

Vitiligo thresholdMore than 10% of body surface area involved

Pityriasis lichenoides chronica thresholdMore than 10% of body surface involved when the condition is widespread

Alternative criterionVitiligo or pityriasis lichenoides chronica may also qualify when unresponsive to conservative therapy

Purchase price for E0691-E0694 equipment

Equipment codesE0691-E0694

Prior approvalNot required when the purchase price is under the outlined thresholds

Threshold amountsThe policy text provided does not state the dollar amounts of the outlined thresholds

Documentation Required

Document Failure of Conservative Therapy

Document that the covered condition is severe, refractory, or otherwise meets the policy’s severity criteria and that appropriate conservative treatment was inadequate or unsuccessful where required.

Record the conservative therapies attempted, such as topical corticosteroids, coal/tar preparations, ultraviolet light, or other appropriate treatment.
Document the duration, adequacy, response, and reason for discontinuation or failure of each relevant therapy.

Documentation Required

Clinical Necessity Documentation

Support medical necessity with a complete clinical assessment and treatment rationale for the requested light therapy.

Diagnosis and applicable disease subtype
Disease severity, including body-surface-area involvement and relevant lesion characteristics
Prior treatments, response, and failure or intolerance
Functional or quality-of-life impact when relevant
The rationale for selecting the requested modality and course of treatment

Documentation Required

Document Home-System Medical Necessity

For home ultraviolet light systems (HCPCS E0691-E0694), document the qualifying condition and show that the disease is refractory and that topical regimens have failed.

Qualifying condition, including extensive psoriasis, severe atopic dermatitis, severe pruritis, cutaneous T-cell lymphoma, qualifying vitiligo, morphea, or pityriasis lichenoides chronica
Failure of adequate topical-regimen trials, with disease described as unmanageable or resistant to treatment
Initial need for ultraviolet light treatment at least 3 times weekly
Beneficial outpatient phototherapy with an expected long-term need
Prescription by a dermatologist

Documentation Required

Monitor PUVA Therapy

Monitor patients receiving PUVA regularly for treatment effectiveness and adverse effects. Adjust exposure so radiation is kept to the minimum compatible with adequate disease control.

Record ongoing clinical response and relevant adverse effects.
Document dose or exposure management and the rationale for continued treatment.

Denial Risk

Watch for Noncovered Indications

Do not submit light therapy as medically necessary for indications excluded by the policy. Light therapy alone for actinic keratosis and treatment of unlisted indications are not medically necessary.

Photodynamic therapy for actinic keratosis is addressed under a separate policy.
All indications not listed as medically necessary are not medically necessary under this policy.

Denial Risk

Home-Based PUVA Not Medically Necessary

Home-based psoralens with ultraviolet A (PUVA) are not medically necessary. PUVA generally requires regular assessment and is not recommended for home therapy.

Denial Risk

Targeted Phototherapy Investigational Uses

Treat targeted phototherapy as investigational for the specified indications and do not represent these uses as covered medically necessary services.

First-line treatment of mild psoriasis
Generalized psoriasis or psoriatic arthritis
Treatment of vitiligo

Denial Risk

Home-System Criteria Must All Be Met

A home ultraviolet light system is not medically necessary unless every required home-system criterion is documented. Identify and resolve any missing criterion before requesting or dispensing the system.

Qualifying diagnosis or disease involvement
Refractory disease with failed adequate topical regimens
Initial treatment need of at least 3 times weekly
Beneficial outpatient phototherapy with expected long-term use
Dermatologist prescription

Denial Risk

Missing Prior Approval Creates Denial Risk

Claims for the listed CPT services may be denied when prior approval was not obtained before the service was provided or billed.

Confirm approval requirements before scheduling or performing CPT 96900, 96910, 96912, 96913, or 96920-96922.
Retain the approval documentation with the claim and medical record.

Billing Rule

Unlisted Codes Require Medical Review

Unlisted services require medical review rather than routine adjudication. Submit supporting clinical documentation and the requested service details.

CPT 96999 — Unlisted special dermatological service or procedure; suspend for medical review
HCPCS J8999 — Suspend for medical review

Ultraviolet light is focused on specific body areas or lesions

Device comparisonTargeted ultraviolet devices are comparable with ultraviolet light panels for treatment purposes

Related devicesLasers and targeted ultraviolet B lamps are considered equivalent devices

Ultraviolet laser treatment code ranges

CPT 96920Ultraviolet light laser treatment for inflammatory disease (psoriasis), total treated area less than 250 cm²

CPT 96921Ultraviolet light laser treatment for inflammatory disease (psoriasis), total treated area 250 cm² to 500 cm²

CPT 96922Ultraviolet light laser treatment for inflammatory disease (psoriasis), total treated area greater than 500 cm²

Eligible providers

Eligible providerQualified healthcare professional

Practice requirementPracticing within the scope of the provider's license(s)

Licensure standardServices must be provided within the professional license scope